Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 8:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Purdue Pharma LP Clear all
Completed Phase 3 Interventional Results available

Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period.

NCT01400139
View directory record Official record
Conditions
Chronic Nonmalignant and Nonneuropathic Pain
Interventions
Hydrocodone bitartrate q24h film-coated tablets
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
922 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
98
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Sep 1, 2026, 8:37 PM EDT
Completed Phase 1 Interventional Results available

Study of V117957 in Overactive Bladder Syndrome

NCT06024642
View directory record Official record
Conditions
Overactive Bladder Syndrome
Interventions
V117957, Placebo
Drug
Lead sponsor
Imbrium Therapeutics
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
12
States / cities
Tucson, Arizona • Canoga Park, California • Long Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Sep 1, 2026, 8:37 PM EDT
Terminated Phase 2 Interventional

An Analgesic Study to of V117957 for the Treatment of Postsurgical Pain Due to Third Molar Extraction

NCT01900795
View directory record Official record
Conditions
Postsurgical Pain Due to Third Molar Extraction
Interventions
V117957, Ibuprofen, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 45 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Sep 1, 2026, 8:37 PM EDT
Completed Phase 1 Interventional Results available

Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome

NCT06285214
View directory record Official record
Conditions
Interstitial Cystitis/Bladder Pain Syndrome
Interventions
V117957, Placebo
Drug
Lead sponsor
Imbrium Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
24
States / cities
Homewood, Alabama • Tucson, Arizona • Little Rock, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 1, 2026, 8:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets

NCT01101191
View directory record Official record
Conditions
Healthy
Interventions
Reformulated OXY (oxycodone HCl), Original OxyContin® (OXY) (oxycodone HCl)
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated May 24, 2010 · Synced Sep 1, 2026, 8:37 PM EDT
Completed Phase 3 Interventional Results available

Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee

NCT00531427
View directory record Official record
Conditions
Chronic Pain, Osteoarthritis of the Knee
Interventions
Buprenorphine, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
87
States / cities
Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Sep 1, 2026, 8:37 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Osteoarthritis Pain

NCT00312221
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine, oxycodone immediate-release
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
23
States / cities
Birmingham, Alabama • Chula Vista, California • Roseville, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Sep 1, 2026, 8:37 PM EDT
Completed Phase 2 Interventional

Safety of the Buprenorphine Transdermal Delivery System in Subjects With Mod-to-Sev Pain Following Orthopedic Surgery.

NCT00315835
View directory record Official record
Conditions
Postoperative Pain
Interventions
Buprenorphine transdermal delivery system
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1997
U.S. locations
1
States / cities
Plantation, Florida
Source: ClinicalTrials.gov public record
Updated Apr 18, 2006 · Synced Sep 1, 2026, 8:37 PM EDT
Completed No phase listed Observational Results available

Effect of Wearable Health Technology on Patients Treated for Chronic Pain at Geisinger Health System

NCT03299556
View directory record Official record
Conditions
Chronic Pain
Interventions
WHT
Other
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 75 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 1, 2026, 8:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets

NCT01101165
View directory record Official record
Conditions
Healthy
Interventions
Reformulated OXY (oxycodone HCl), Original OxyContin® (OXY) (oxycodone HCl)
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 50 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated May 10, 2010 · Synced Sep 1, 2026, 8:37 PM EDT
Completed Phase 2 Interventional Results available

Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia

NCT03001557
View directory record Official record
Conditions
Irregular Sleep-Wake Rhythm Disorder
Interventions
Lemborexant 2.5 mg, Lemborexant 5 mg, Lemborexant 10 mg, Lemborexant 15 mg, Lemborexant-matched placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
60 Years to 90 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
37
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Costa Mesa, California + 30 more
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Sep 1, 2026, 8:37 PM EDT
Completed Phase 3 Interventional Results available

Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study

NCT01151098
View directory record Official record
Conditions
Chronic Nonmalignant Pain
Interventions
Buprenorphine transdermal patch
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
19
States / cities
Phoenix, Arizona • Trumbull, Connecticut • Clearwater, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Sep 1, 2026, 8:37 PM EDT
Completed Phase 3 Interventional

A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD

NCT02555150
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
PRC-063, lisdexamfetamine dimesylate, Placebo
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
18 Years to 35 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Sep 1, 2026, 8:37 PM EDT
Completed Phase 3 Interventional

A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain

NCT01427283
View directory record Official record
Conditions
Low Back Pain
Interventions
Oxycodone/Naloxone controlled-release, Oxycodone HCl controlled-release, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
149
States / cities
Alabaster, Alabama • Birmingham, Alabama • Foley, Alabama + 114 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2015 · Synced Sep 1, 2026, 8:37 PM EDT
Completed Phase 3 Interventional Results available

Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Chronic Low Back Pain

NCT00490919
View directory record Official record
Conditions
Low Back Pain
Interventions
Buprenorphine transdermal system, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
86
States / cities
Anniston, Alabama • Mobile, Alabama • Chandler, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Sep 1, 2026, 8:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets

NCT01100320
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Reformulated OXY (oxycodone HCl), Original OxyContin® (OXY) (oxycodone HCl)
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 50 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2010 · Synced Sep 1, 2026, 8:37 PM EDT
Completed Phase 3 Interventional

Safety and Effectiveness of Buprenorphine Transdermal System in Elderly Subjects With Chronic Pain: Pilot Study.

NCT00313833
View directory record Official record
Conditions
Chronic Pain
Interventions
Buprenorphine transdermal delivery system
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
55 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 2, 2006 · Synced Sep 1, 2026, 8:37 PM EDT
Terminated Phase 3 Interventional Results available

Buprenorphine Transdermal Patch in Subjects With Osteoarthritis Pain Requiring Opioids. Includes a 52-Week Safety Extension.

NCT00315458
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal patch, Placebo transdermal patch
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
48
States / cities
Birmingham, Alabama • Haleyville, Alabama • Muscle Shoals, Alabama + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2012 · Synced Sep 1, 2026, 8:37 PM EDT
Terminated Phase 3 Interventional

Efficacy and Safety of Hydromorphone Hydrochloride Extended-Release Compared to Placebo in Subjects With Persistent Pain

NCT00365898
View directory record Official record
Conditions
Chronic Non-Malignant Pain
Interventions
Hydromorphone Hydrochloride Extended-Release
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
14
States / cities
Phoenix, Arizona • Clearwater, Florida • Fort Myers, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2006 · Synced Sep 1, 2026, 8:37 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.

NCT00314652
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal delivery system
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999
U.S. locations
22
States / cities
Phoenix, Arizona • Tucson, Arizona • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 2, 2006 · Synced Sep 1, 2026, 8:37 PM EDT
Completed Phase 3 Interventional Results available

Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids

NCT01192295
View directory record Official record
Conditions
Pain
Interventions
Oxycodone HCl controlled-release tablets
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
6 Years to 16 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
35
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2020 · Synced Sep 1, 2026, 8:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Hydrocodone Bitartrate (HYD) Extended-Release Tablets on QT /QTc Intervals in Healthy Adult Subjects

NCT02243241
View directory record Official record
Conditions
Healthy
Interventions
HYD, Moxifloxacin, Placebo for HYD, Placebo for moxifloxacin
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 50 Years
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Sep 1, 2026, 8:37 PM EDT
Completed Phase 2 Interventional

Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis (OA) of the Knee

NCT01688934
View directory record Official record
Conditions
Osteoarthritis, Knee, Pain
Interventions
V116517 50-mg tablets, V116517 30-mg tablets, Naproxen 500-mg capsules, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years to 80 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
18
States / cities
Tucson, Arizona • Boynton Beach, Florida • DeLand, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Sep 1, 2026, 8:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Determine the Fasting Bioequivalence of Reformulated OXY Tablets Manufactured at Two Different Facilities

NCT01101321
View directory record Official record
Conditions
Healthy
Interventions
Reformulated OXY (Totowa) (oxycodone HCl), Reformulated OXY (Wilson) (oxycodone HCl)
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 50 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Sep 1, 2026, 8:37 PM EDT